This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

DaVita Clinical Research And Pyxant Labs To Collaborate On Clinical Trials

MINNEAPOLIS, Feb. 12, 2014 /PRNewswire-USNewswire/ -- DaVita Clinical Research ® (DCR ®), a specialty contract research organization with services spanning the full spectrum of drug and device development, announced today that it has entered into an agreement through which Pyxant Labs Inc. will provide bioanalytical laboratory services for DCR's early clinical trials.

(Logo: http://photos.prnewswire.com/prnh/20140212/DC63568LOGO)

"Pyxant's proven track record and overall commitment to high quality aligns well with our strategic growth objectives for early clinical research," said Chad Jaeger, vice president of early clinical research at DCR. "This collaboration represents another step forward in providing comprehensive services aimed at accelerating drug development."

Pyxant Labs is a contract research laboratory specializing in GLP bioanalytical chemistry support for life sciences clients. As part of the relationship, Pyxant will provide bioanalytical method development, sample analysis and formulation development for early clinical trials conducted at DCR's clinical research units.

"We are excited to further extend our collaboration with the great team at DCR. DCR has built the best clinical research site that I have toured in the last 10 years. Their operations team at the site, corporate culture and high ethical approach made a compelling case for our association," said Maurice Gaubatz, president and CEO of Pyxant Labs. "Pairing DCR's clinical execution with Pyxant's bioanalytical services is a winning combination, exactly in line with our respective core competencies." 

To learn more about DCR and upcoming clinical research trials, visit participateDaVita.com or DCR on Facebook.

DaVita HealthCare Partners, DaVita Clinical Research, and DCR are trademarks or registered trademarks of DaVita HealthCare Partners Inc. Pyxant and Pyxant Labs are trademarks or registered trademarks of Pyxant Labs Inc. All other trademarks are the property of their respective owners.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,130.22 +33.32 0.18%
S&P 500 2,101.01 +2.48 0.12%
NASDAQ 4,981.98 +14.8390 0.30%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs